Mykoderm (Miconazole Nitrate)

Miconazole nitrate inhibits the fungal enzyme lanosterol 14α‑demethylase, which is essential for converting lanosterol to ergosterol, a key component of fungal cell membranes. By blocking this step, the drug disrupts membrane integrity, leading to increased permeability, loss of cellular contents and ultimately fungal cell death. The inhibition is concentration‑dependent and occurs locally at the site of application, providing targeted antifungal activity with minimal systemic absorption.

The dosing regimen for Mykoderm is determined by the prescribing healthcare professional based on the specific infection, severity, patient age and treatment guidelines. Typically, a thin layer is applied to the affected area once or twice daily for the period recommended by the clinician. Patients should follow the label instructions and the prescriber’s advice without altering the frequency or duration on their own.

Safety data for topical miconazole nitrate in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers generally weigh the benefits against potential risks before prescribing it to pregnant or nursing women. If treatment is considered necessary, the prescriber may advise limited use on small skin areas and monitor both mother and infant closely.

To request Mykoderm, visit the product page on gnhindia.com, enter the desired quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials. After verification, the sales team provides a quotation, confirms availability, outlines shipping conditions (including any temperature controls) and assists with the required import documentation.

Mykoderm’s active ingredient, miconazole nitrate, belongs to the imidazole class and offers broad‑spectrum activity against dermatophytes and yeasts. Compared with allylamine agents such as terbinafine, miconazole provides a rapid fungistatic effect and is available over‑the‑counter in many markets. It is generally well tolerated, but may cause more local irritation than some newer azole formulations. Choice of therapy depends on infection type, patient preference, cost and clinician experience.

Mykoderm should be stored at room temperature, preferably below 25 °C (77 °F). Keep the container tightly closed, protect it from moisture, direct sunlight and extreme heat. Do not freeze the product. If the formulation appears discoloured, separated or has an unusual odor, discard it and obtain a fresh supply. Proper storage helps maintain potency and prevents degradation.

Mykoderm is applied directly to clean, dry skin in a thin layer covering the affected area. The recommended amount is usually a fingertip‑unit or as directed by the prescriber. After spreading, allow the medication to dry before dressing the area or putting on clothing. Hands should be washed before and after application, and contact with eyes, mouth or mucous membranes should be avoided.

Although rare, serious adverse reactions can occur. These include severe contact dermatitis, extensive swelling, blister formation, widespread rash and systemic hypersensitivity such as anaphylaxis. If any of these symptoms develop—especially difficulty breathing, swelling of the face or throat, or a rapidly spreading rash—immediate medical attention is required. Prompt discontinuation of the product and evaluation by a healthcare professional are essential.

Mykoderm should be avoided in individuals with a known hypersensitivity to miconazole nitrate or any other component of the formulation. It is also not recommended for use on extensive broken skin, deep fungal infections that require systemic therapy, or in patients where a physician has advised alternative treatment. Children under two months of age should not receive the product unless specifically directed by a qualified clinician.